125 related articles for article (PubMed ID: 38735515)
1. Stable hemoglobin concentration with fecal immunochemical test at high temperatures in a Caribbean colorectal cancer screening program.
Blake SN; Kortlever TL; Verbrugge SE; van Vuuren AJ; Dekker E; van der Vlugt M; Hugtenburg JG
Clin Chim Acta; 2024 Jun; 560():119723. PubMed ID: 38735515
[TBL] [Abstract][Full Text] [Related]
2. Direct comparison of ten quantitative fecal immunochemical tests for hemoglobin stability in colorectal cancer screening.
Gies A; Cuk K; Schrotz-King P; Brenner H
Clin Transl Gastroenterol; 2018 Jul; 9(7):168. PubMed ID: 29976921
[TBL] [Abstract][Full Text] [Related]
3. Effect of Temperature and Time on Fecal Hemoglobin Stability in 5 Fecal Immunochemical Test Methods and One Guaiac Method.
Catomeris P; Baxter NN; Boss SC; Paszat LF; Rabeneck L; Randell E; Serenity ML; Sutradhar R; Tinmouth J
Arch Pathol Lab Med; 2018 Jan; 142(1):75-82. PubMed ID: 28967803
[TBL] [Abstract][Full Text] [Related]
4. Are fecal immunochemical test characteristics influenced by sample return time? A population-based colorectal cancer screening trial.
van Roon AH; Hol L; van Vuuren AJ; Francke J; Ouwendijk M; Heijens A; Nagtzaam N; Reijerink JC; van der Togt AC; van Ballegooijen M; Kuipers EJ; van Leerdam ME
Am J Gastroenterol; 2012 Jan; 107(1):99-107. PubMed ID: 22108450
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the stability of fecal immunochemical test specimens.
Reid MS; Paul HA; Mostoufi A; Robinson JL; Sadrzadeh SMH
Clin Biochem; 2023 May; 115():92-96. PubMed ID: 36470343
[TBL] [Abstract][Full Text] [Related]
6. Colorectal Cancer Screening by Fecal Immunochemical Tests (FIT): Considerations on Sampling and Markers (Hb and Hb/Hp Complex) of Fecal Occult Blood (FOB).
Syrjänen K; Eskelinen M; Meklin J; Hendolin P; Eskelinen M; Suovaniemi O
Anticancer Res; 2024 Apr; 44(4):1513-1523. PubMed ID: 38537972
[TBL] [Abstract][Full Text] [Related]
7. Impact of a new sampling buffer on faecal haemoglobin stability in a colorectal cancer screening programme by the faecal immunochemical test.
Grazzini G; Ventura L; Rubeca T; Rapi S; Cellai F; Di Dia PP; Mallardi B; Mantellini P; Zappa M; Castiglione G
Eur J Cancer Prev; 2017 Jul; 26(4):285-291. PubMed ID: 27271031
[TBL] [Abstract][Full Text] [Related]
8. Impact of a higher fecal immunochemistry test cut-off on pathology detected in subsequent rounds of a colorectal screening program.
Gibson DJ; Mooney T; Mooney J; Mulcahy HE; O'Donoghue D
Gastrointest Endosc; 2019 Mar; 89(3):518-522. PubMed ID: 30142350
[TBL] [Abstract][Full Text] [Related]
9. Fresh vs Frozen Samples and Ambient Temperature Have Little Effect on Detection of Colorectal Cancer or Adenomas by a Fecal Immunochemical Test in a Colorectal Cancer Screening Cohort in Germany.
Chen H; Werner S; Brenner H
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1547-1556.e5. PubMed ID: 27793749
[TBL] [Abstract][Full Text] [Related]
10. Fecal immunochemical test in colorectal cancer screening: Colonoscopy findings by different cut-off levels.
Ribbing Wilén H; Blom J; Höijer J; Hultcrantz R
J Gastroenterol Hepatol; 2019 Jan; 34(1):103-112. PubMed ID: 29968937
[TBL] [Abstract][Full Text] [Related]
11. Influence of sample return time and ambient temperature on the performance of an immunochemical faecal occult blood test with a new buffer for colorectal cancer screening.
Dancourt V; Hamza S; Manfredi S; Drouillard A; Bidan JM; Faivre J; Lepage C
Eur J Cancer Prev; 2016 Mar; 25(2):109-14. PubMed ID: 25830897
[TBL] [Abstract][Full Text] [Related]
12. An Exploratory Analysis of Fecal Immunochemical Test Performance for Colorectal Cancer Screening in Nigeria.
Knapp GC; Sharma A; Olopade B; Alatise OI; Olasehinde O; Arije OO; Castle PE; Kingham TP
World J Surg; 2019 Nov; 43(11):2674-2680. PubMed ID: 31407091
[TBL] [Abstract][Full Text] [Related]
13. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test.
Vilkin A; Rozen P; Levi Z; Waked A; Maoz E; Birkenfeld S; Niv Y
Am J Gastroenterol; 2005 Nov; 100(11):2519-25. PubMed ID: 16279909
[TBL] [Abstract][Full Text] [Related]
14. A New-Generation Fecal Immunochemical Test (FIT) Is Superior to Quaiac-based Test in Detecting Colorectal Neoplasia Among Colonoscopy Referral Patients.
Vasilyev S; Smirnova E; Popov D; Semenov A; Eklund C; Hendolin P; Paloheimo L; Syrjänen K
Anticancer Res; 2015 May; 35(5):2873-80. PubMed ID: 25964570
[TBL] [Abstract][Full Text] [Related]
15. Analytical comparison of three quantitative immunochemical fecal occult blood tests for colorectal cancer screening.
Guittet L; Guillaume E; Levillain R; Beley P; Tichet J; Lantieri O; Launoy G
Cancer Epidemiol Biomarkers Prev; 2011 Jul; 20(7):1492-501. PubMed ID: 21576271
[TBL] [Abstract][Full Text] [Related]
16. Fecal immunochemical test in cancer screening - colonoscopy outcome in FIT positives and negatives.
Ribbing Wilén H; Blom J; Höijer J; Andersson G; Löwbeer C; Hultcrantz R
Scand J Gastroenterol; 2019 Mar; 54(3):303-310. PubMed ID: 30907196
[No Abstract] [Full Text] [Related]
17. The multitarget fecal immunochemical test versus the fecal immunochemical test for programmatic colorectal cancer screening: a cross-sectional intervention study with paired design.
Wisse PHA; de Klaver W; van Wifferen F; Meiqari L; Bierkens M; Greuter MJE; Carvalho B; van Leerdam ME; Spaander MCW; Dekker E; Coupé VMH; de Wit M; Meijer GA
BMC Cancer; 2022 Dec; 22(1):1299. PubMed ID: 36503495
[TBL] [Abstract][Full Text] [Related]
18. Effects of Increasing Screening Age and Fecal Hemoglobin Cutoff Concentrations in a Colorectal Cancer Screening Program.
Wieten E; Schreuders EH; Nieuwenburg SA; Hansen BE; Lansdorp-Vogelaar I; Kuipers EJ; Bruno MJ; Spaander MC
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1771-1777. PubMed ID: 27567693
[TBL] [Abstract][Full Text] [Related]
19. Personalized colorectal cancer screening: study protocol of a mixed-methods study on the effectiveness of tailored intervals based on prior f-Hb concentration in a fit-based colorectal cancer screening program (PERFECT-FIT).
Breekveldt ECH; Toes-Zoutendijk E; de Jonge L; Spaander MCW; Dekker E; van Kemenade FJ; van Vuuren AJ; Ramakers CRB; Nagtegaal ID; van Leerdam ME; Lansdorp-Vogelaar I
BMC Gastroenterol; 2023 Feb; 23(1):45. PubMed ID: 36814185
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with interval colorectal cancer after negative FIT: Results of two screening rounds in the Dutch FIT-based CRC screening program.
Breekveldt ECH; Toes-Zoutendijk E; van de Schootbrugge-Vandermeer HJ; de Jonge L; Kooyker AI; Spaander MCW; van Vuuren AJ; van Kemenade FJ; Ramakers C; Dekker E; Nagtegaal ID; van Leerdam ME; Lansdorp-Vogelaar I
Int J Cancer; 2023 Apr; 152(8):1536-1546. PubMed ID: 36444504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
